Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide

Table 1

Baseline patient and disease characteristics.

Characteristic	Whole cohort; ()	L-PIV; ()	H-PIV; ()	value
Median age, (range)	58 (21-80)	60 (34-80)	57 (21-79)	0.73
Age group, (%)
< 50 years	65 (31.9)	24 (32.0)	41 (32.2)	0.85
≥ 50 years	139 (68.1)	51 (68.0)	88 (68.2)
Gender, (%)
Female	69 (33.8)	27 (36.0)	42 (32.6)	0.32
Male	135 (66.2)	48 (64.0)	87 (67.4)
ECOG, (%)
0	122 (59.8)	44 (58.7)	78 (60.5)	0.71
1	82 (40.2)	31 (41.3)	51 (39.5)
RTOG RPA class, (%)
III	79 (38.7)	29 (38.7)	50 (38.8)	0.91
IV	84 (41.1)	31 (41.3)	53 (41.1)
V	41 (20.2)	15 (20.0)	26 (20.1)
Median symptom duration, months (range)	2.1 (0.3-6.2)	2.3 (0.3-6.2)	1.9 (0.3- 4.8)	0.43
Symptom duration group, (%)
< 3 months	148 (72.5)	55 (73.3)	93 (72.1)	0.88
≥ 3 months	56 (27.5)	20 (26.7)	36 (27.9)
Extent of surgery, (%)
Gross total	71 (34.8)	25 (33.3)	46 (35.7)	0.69
Subtotal	99 (48.5)	38 (50.7)	61 (47.3)
Biopsy	34 (16.7)	16 (16.0)	9 (17.0)
Anticonvulsant use, n (%)
Yes	76 (37.3)	27 (36.0)	49 (38.0)	0. 48
No	128 (62.7)	48 (64.0)	80 (62.0)
Corticosteroid use, (%)
Yes	114 (67.1)	41 (54.7)	73 (56.6)	0.54
No	90 (29.9)	34 (45.3)	56 (33.4)

Abbreviations: L-PIV: low pan-immune-inflammation value; H-PIV: high pan-immune-inflammation value; ECOG: Eastern Cooperative Oncology Group; RTOG RPA: Radiation Therapy Oncology Group recursive partitioning analysis.